Fundz

Catalym Closes Eur 50 Million Series C Financing To Expand And Accelerate Phase 2 Clinical Development Of Visugromab In Patients With Solid Tumors

PRIVATENov 22, 2022

Amount Raised

€50 Million

Round Type

Series C

MunichBiotechnologyHealth Care

Investors

Bio Generation VenturesForbion, Novartis Venture FundJeito CapitalBrandon Capital

Description

CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.

Quick answer

CatalYm raised €50 Million in a Series C round, dated November 22, 2022. Investors: Bio Generation Ventures, Forbion, Novartis Venture Fund, Jeito Capital and Brandon Capital. CatalYm is based in Munich, Bavaria, Germany.

How much did CatalYm raise?
CatalYm raised €50 Million in a Series C round on November 22, 2022.
Who invested in CatalYm?
Bio Generation Ventures, Forbion, Novartis Venture Fund, Jeito Capital and Brandon Capital are named as investors in this round.
What does CatalYm do?
CatalYm is developing visugromab, a first-in-class anti-GDF-15 antibody, in solid tumors and other indications.
Where is CatalYm based and how big is it?
CatalYm is based in Munich, Bavaria, Germany. Fundz records about 57 employees.
Who are the decision-makers at CatalYm?
Fundz holds 2 contacts at CatalYm, including the Head Clinical Operations. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at CatalYm, and when

A new round usually means CatalYm is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CatalYm raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CatalYm, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CatalYm. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CatalYm

Location

Munich, Bavaria, Germany

About

CatalYm is developing visugromab, a first-in-class anti-GDF-15 antibody, in solid tumors and other indications. In its first-in-human Phase 1/2a study, visugromab demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. In addition, data from the same study demonstrated that visugromab can significantly counteract the effects of cachexia in these patients. This data was recently published in Nature and presented at the International Conference on Sarcopenia, Cachexia & Wasting Disorders. CatalYm is now advancing visugromab into multiple Phase 2b studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CatalYm raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsPetra F., Head Clinical Operations hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for CatalYm's next move

See what Strategic adds

CatalYm raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.